Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

the most surprising aspect of the earnings release was that Regeneron declared a dividend for the first time in its history, of $0.88 per quarter, which translates to an annual yield of ~0.53% - a ...

Regeneron Pharmaceuticals announced that the ... in the company's manufacturing processes. The FDA's extended timeline for a decision until July 10, 2025, may reflect uncertainties about the ...